PTPRN (protein tyrosine phosphatase receptor type N) is a membrane receptor protein that lacks conventional protein tyrosine phosphatase activity due to mutations in its catalytic domain, but has acquired distinct roles in neuroendocrine cells 1. The protein is expressed in neuroendocrine tissues including the hypothalamus, pituitary gland, pancreas, lung, and intestine 1. In pancreatic beta-cells, PTPRN regulates insulin secretion through two mechanisms: its cytoplasmic fragment (ICA512-CCF) controls insulin granule dynamics and exocytosis, while its nuclear translocation promotes insulin gene expression by interacting with STAT5B transcription factors 1. PTPRN has significant disease relevance, particularly in cancer. In glioblastoma, high PTPRN expression correlates with poor prognosis and promotes tumor cell proliferation and migration through activation of the PI3K/AKT pathway via interaction with HSP90AA1 2. The protein has been identified as a potential therapeutic target, with several studies incorporating PTPRN into prognostic models for glioblastoma survival prediction 345. Additionally, PTPRN shows associations with diabetic kidney disease in genome-wide studies 6. These findings suggest PTPRN plays crucial roles in both normal neuroendocrine function and pathological processes.